Astellas Pharma Inc. Release: New Phase II Data Demonstrates Significant Activity of Quizartinib in Relapsed or Refractory AML Patients

ATLANTA--(BUSINESS WIRE)--Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation today announced the results from a completed phase II study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML).1,2 These data from two study cohorts (patients aged = 60 years with AML relapsed in <1 year or refractory to 1st-line chemotherapy; patients aged = 18 years with AML relapsed or refractory to second line, salvage chemotherapy or relapsed after HSCT) were presented at the American Society of Haematology (ASH) meeting in Atlanta, Georgia. Combined results from the two cohorts included: Approximately 50 percent of FLT3-ITD positive patients achieved a composite complete response (CRc = complete remission (CR) + complete remission with incomplete platelet recovery (CRp) + complete remission with incomplete hematologic recovery (CRi))1,2